

Meeting Report



OPEN ACCESS

Received: Sep 2, 2024

Accepted: Apr 30, 2025

Published online: Aug 11, 2025

Correspondence to

Yong-Man Kim

Department of Obstetrics and Gynecology,
Asan Medical Center, University of Ulsan
College of Medicine, 88 Olympic-ro 43-gil,
Songpa-gu, Seoul 05505, Korea.
Email: amcymkim@gmail.com

© 2025. Asian Society of Gynecologic
Oncology, Korean Society of Gynecologic
Oncology, and Japan Society of Gynecologic
Oncology

This is an Open Access article distributed
under the terms of the Creative Commons
Attribution Non-Commercial License (<https://creativecommons.org/licenses/by-nc/4.0/>)
which permits unrestricted non-commercial
use, distribution, and reproduction in any
medium, provided the original work is properly
cited.

ORCID iDs

Shin-Wha Lee 
<https://orcid.org/0000-0002-5088-1905>
So Hyun Nam 
<https://orcid.org/0000-0002-4921-6684>
Chyong-Huey Lai 
<https://orcid.org/0000-0002-9977-9645>
Aikou Okamoto 
<https://orcid.org/0000-0002-5079-0464>
Jae-Hoon Kim 
<https://orcid.org/0000-0001-6599-7065>
Takayuki Enomoto 
<https://orcid.org/0000-0003-4538-5541>
Yong Man Kim 
<https://orcid.org/0000-0003-3225-5748>

The 2nd Annual Meeting of the East Asian Gynecologic Oncology Trial Group (EAGOT)

Shin-Wha Lee ¹, **So Hyun Nam** ¹, **Chyong-Huey Lai** ², **Xiaohua Wu**,³
Aikou Okamoto ⁴, **Jae-Hoon Kim** ⁵, **Takayuki Enomoto** ⁶, **Yong-Man Kim** ¹

¹Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

²Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital, Linkou Branch and Chang Gung University, Taoyuan, Taiwan

³Department of Gynecological Oncology, Fudan University Shanghai Cancer Center, Shanghai, China

⁴Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo, Japan

⁵Department of Obstetrics and Gynecology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea

⁶Department of Obstetrics and Gynecology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan

INTRODUCTION

On November 19, 2021, 4 clinical trial organizations—the Japanese Gynecologic Oncology Group (JGOG), the Korean Gynecologic Oncology Group (KGOG), the Taiwanese Gynecologic Oncology Group (TGOG), and the Chinese Gynecologic Cancer Society (CGCS)—united to form the East Asian Gynecologic Oncology Trial Group (EAGOT). The EAGOT 1st Annual Meeting was held on May 25 to 27, 2023, in Niigata, Japan, with Professor Takayuki Enomoto (the previous past president of EAGOT) serving as the congress chair. The EAGOT 2nd Annual Meeting took place in Seoul, Korea, from September 1 to 3, 2023, with Professor Yong Man Kim, the immediate past president of EAGOT, serving as the congress chair. **Table 1** shows a list of members in each committee of the EAGOT in 2023. The overall schedule of the EAGOT 2nd Annual Meeting is shown in **Fig. 1**.

DAY 1 (SOFITEL HOTEL, SEOUL): INDUSTRIAL SYMPOSIUM 1 AND WELCOME DINNER

On the first day of the Annual Meeting, a seminar sponsored by Kyongbo Pharma was conducted at the Hotel Sofitel in Seoul, with Professor Young Tak Kim, the president of Asia-Oceania Research Organization in Genital Infection and Neoplasia (AOGIN), serving as the chair. Professor Ha-Kyun Chang presented a lecture entitled “Post operative medical care: focused on pain management with acetaminophen & ibuprofen (Maxigesic N).” He summarized the pharmacological mechanism and analgesic effects of the combination analgesic containing acetaminophen and ibuprofen in patients who have undergone gynecologic surgery. Professor Chi-Hum Cho (the president of Asian Society for Gynecologic Robotic Surgery) presented a lecture entitled “ERAS protocol of GYN robotic surgery.” He presented on the efficacy and safety of the enhanced recovery after surgery (ERAS) protocol in the management of gynecologic patients undergoing robotic surgery. After

The 2nd Annual Meeting report of EAGOT

Table 1. EAGOT members of each committee in 2023

EAGOT	First name	Last name	Group	Affiliation	EAGOT 2nd Annual Meeting
President	Yong Man	Kim	KGOG	Asan Medical Center	On-site
Immediate past president	Takayuki	Enomoto	JGOG	Niigata University Graduate School of Medical and Dental Sciences	On-site
Council	Chyong-Huey	Lai	TGOG	Chang Gung Memorial Hospital, Linkou Branch	On-site
Council/Ovarian cancer committee	Xiaohua	Wu	CGCS	Fudan University Shanghai Cancer Center	On-site
Council	Aikou	Okamoto	JGOG	The Jikei University School of Medicine	On-site
Council	Jae-Hoon	Kim	KGOG	Gangnam Severance Hospital, Yonsei University College of Medicine	On-site
Council	Jae-Weon	Kim	KGOG	Seoul National University College of Medicine	On-site
Council/Cervical cancer committee	Jihong	Liu	CGCS	Sun Yat-sen University Cancer Center	-
Council	Masaki	Mandai	JGOG	Kyoto University Graduate School of Medicine and Faculty of Medicine	-
Council/Uterine corpus cancer committee	Ting Chang	Chang	TGOG	Chang Gung Memorial Hospital, Linkou Branch	On-site
Cervical cancer committee	Qi	Zhou	CGCS	Chongqing University Cancer Hospital	On-site
Cervical cancer committee	Munetaka	Takekuma	JGOG	Shizuoka Cancer Center	-
Cervical cancer committee	Hiroyuki	Kanao	JGOG	Cancer Institute Hospital of JFCR	-
Cervical cancer committee	Keun-Ho	Lee	KGOG	The Catholic University of Korea, Seoul St. Mary's Hospital	On-site
Cervical cancer committee	Sang-Wun	Kim	KGOG	Severance Hospital	On-site
Cervical cancer committee	You-Chen	Wang	TGOG	Chang Gung Memorial Hospital	On-site
Cervical cancer committee	Peng-Hui	Wang	TGOG	Taipei Veteran General Hospital	On-site
Uterine corpus cancer committee	Danbo	Wang	CGCS	Liaoning Cancer Hospital & Institute	-
Uterine corpus cancer committee	Shiqian	Zhang	CGCS	Will Hospital of Shandong University	-
Uterine corpus cancer committee	Wataru	Yamagami	JGOG	Keio University	-
Uterine corpus cancer committee	Yoshihito	Yokoyama	JGOG	Hirotsuki University	-
Uterine corpus cancer committee	Min-Kyu	Kim	KGOG	Samsung Changwon Hospital	On-site
Uterine corpus cancer committee	Jeong-Yeol	Park	KGOG	Asan Medical Center	On-site
Uterine corpus cancer committee	Chih-Long	Chang	TGOG	Mackay Memorial Hospital	-
Ovarian cancer committee	Zhongqiu	Lin	CGCS	Sun Yat-sen Memorial Hospital Sun Yat-sen University	-
Ovarian cancer committee	Muneaki	Shimada	JGOG	Tohoku University Hospital	On-site
Ovarian cancer committee	Hiroaki	Kajiyama	JGOG	Nagoya University	-
Ovarian cancer committee	Sokbom	Kang	KGOG	National Cancer Center	On-site
Ovarian cancer committee/TR committee	Jeong-Won	Lee	KGOG	Samsung Medical Center	On-site
Ovarian cancer committee	Lin-Hung	Wei	TGOG	National Taiwan University Hospital	On-site
Ovarian cancer committee	Yu-Fang	Huang	TGOG	National Cheng Kung University Hospital	-
TR committee	Yang	Xiang	CGCS	Peking Union Medical College Hospital	-
TR committee	Lingying	Wu	CGCS	Cancer Hospital Chinese Academy of Medical Sciences	-
TR committee	Katsutoshi	Oda	JGOG	University of Tokyo	On-site
TR committee	Kosuke	Yoshihara	JGOG	Niigata University	On-site
TR committee	Sung-Jong	Lee	KGOG	The Catholic University of Korea, Seoul St. Mary's Hospital	On-site
TR committee	Ruby Yun-Ju	Huang	TGOG	National Taiwan University Hospital	On-site
TR committee	Tzu-Yi	Wu	TGOG		-

CGCS, Chinese Gynecologic Cancer Society; EAGOT, East Asian Gynecologic Oncology Trial Group; JFCR, Japanese Foundation for Cancer Research; JGOG, Japanese Gynecologic Oncology Group; KGOG, Korean Gynecologic Oncology Group; TGOG, Taiwanese Gynecologic Oncology Group; TR, translational research.

Conflict of Interest

No potential conflict of interest relevant to this article was reported.

Author Contributions

Conceptualization: L.S.W., L.C.H., W.X., O.A., K.H.J., E.T., K.Y.M.; Data curation: K.Y.M.; Writing - original draft: L.S.W., N.S.H., K.Y.M.; Writing - review & editing: L.S.W., N.S.H., L.C.H., W.X., O.A., K.H.J., E.T., K.Y.M.

the industrial symposium, a welcome dinner was held. At first, Professor Yong Man Kim (the president of EAGOT) delivered the opening remarks, followed by greetings from the presidents of each group: Professor Aikou Okamoto from JGOG, Professor Chyong Huey Lai from TGOG, and Professor Jae Hoon Kim from KGOG. All participants shared a meal together, which provided an opportunity to strengthen their connections and engage in meaningful discussions with one another.

Program at a glance							
The 2nd Annual Meeting of EAGOT							
	Sep. 01 (Fri)	Sep. 02 (Sat)					Sep. 03 (Sun)
	Asan Medical Center	Asan Medical Center					Sofitel Ambassador Seoul
	Conference room 1	Grand auditorium	Conference room 1	Conference room 2	Conference room 3	Sky lounge	Bastille room
8:00			08:00-09:00 Administration committee meeting (closed)	08:00-09:00 Core investigator meeting	08:00-09:00 CRC meeting		08:00-09:00 New protocol development meeting (closed)
9:00		09:00-10:20 Opening & Plenary Session					09:00-11:00 EAGOT general assembly
10:00			10:30-12:30 Cervical cancer committee	10:30-12:30 Translational research committee			
11:00						11:00-12:00 Council meeting	11:00-12:00 Industrial symposium 4 (Canaria Bio)
12:00						12:30-13:30 Luncheon	12:00-13:00 Luncheon
13:00		13:30-14:30 Industrial symposium 2 (Astra-Zeneca)					
14:00					14:30-15:30 EAGOT summit		
15:00	15:00-16:30 SCI symposium		15:00-17:00 Ovarian cancer committee	15:00-17:00 Uterine corpus committee			
16:00							
17:00		17:00-18:00 Industrial symposium 3 (MSD)					
18:00	18:00-19:00 Industrial symposium 1 (KyungBo pharma)	18:30-20:30 Congress banquet (Asan hall)					
19:00	19:00-21:00 Welcome dinner (Sofitel Ambassador Hotel, bastille room)						
20:00							
21:00							

Fig. 1. The program of the EAGOT 2nd Annual Meeting. EAGOT, East Asian Gynecologic Oncology Trial Group.

DAY 2 (ASAN MEDICAL CENTER, SEOUL): THE PLENARY SESSION, THE 4 COMMITTEES, AND THE EAGOT COUNCIL MEETING

On the second day, the conference was held at Asan Medical Center, where a group photo was taken (**Fig. 2**). Following the opening remarks by Professor Yong Man Kim (the president of EAGOT), he introduced the presidents of the member groups: Jae-Hoon Kim of KGOG, Aikou Okamoto of JGOG, Chyong-Huey Lai of TGOG, and Xiaohua Wu of CGCS. Professor Shin Wha Lee (the EAGOT secretary general) introduced the venue and the 2-day schedule. After the opening ceremony, the plenary session and industrial symposium were held together, while the 4 disease committees were conducted separately. The agenda of each session is shown in **Tables 2-5**.

1. Plenary session

First, Professor Angeles Secord (the president of Society of Gynecologic Oncology [SGO]) presented a lecture titled “Clinical Trials Update of GYN Cancer in the USA.” She discussed recently published research findings as well as the protocols and progress of various ongoing clinical trials. Subsequently, Professor Mikio Mikami (the president of JSGO) delivered a lecture on “Surgical Challenges in Cervical Cancer Patients with Involved Lymph Nodes–From Clinical Experience–.” He explained the challenges that can arise during surgery for

cervical cancer cases with lymph node metastasis and provided solutions based on his clinical experience.



Fig. 2. A group photo of the EAGOT 2nd Annual Meeting. EAGOT, East Asian Gynecologic Oncology Trial Group.

Table 2. The agenda of cervical cancer committee in the EAGOT 2nd Annual Meeting

Agenda	Speaker
Introduction of 2nd EAGOT cervical committee and summary from 1st EAGOT	Keun Ho Lee (KGOG)
Clinicopathology characteristic of patients with cervical cancer having received simple hysterectomy (CASH)	Ki Dong Kim (KGOG)
Retrospective multicenter observational study about pelvic radiotherapy for FIGO IVB uterine cervical cancer (JGOG1088S)	Koji Nishino (JGOG)
A phase III randomized clinical trial of laparoscopic or robotic RH using cancer cell spillage minimizing techniques vs abdominal RH in patients with early-stage cervical cancer (MACC)	Dae-Yeon Kim (KGOG)
A non-randomized confirmatory trial of minimum invasive laparoscopic radical hysterectomy (new-Japanese LRH) for patients with early stage cervical cancer (JGOG 1087, JACC trial)	Taichi Mizushima (JGOG)
Overcoming radiation resistance: combination of radiation and immunotherapy	Youn Jin Choi (KGOG)
Panel discussion	Koji Nishino (JGOG) Taichi Mizushima (JGOG) Jihong Liu (CGCS) Peng-Hui Wang (TGOG) Keun Ho Lee (KGOG) Sang Wun Kim (KGOG)

CGCS, Chinese Gynecologic Cancer Society; EAGOT, East Asian Gynecologic Oncology Trial Group; FIGO, International Federation of Gynecology and Obstetrics; JGOG, Japanese Gynecologic Oncology Group; LRH, laparoscopic radical hysterectomy; KGOG, Korean Gynecologic Oncology Group; RH, radical hysterectomy; TGOG, Taiwanese Gynecologic Oncology Group.

Table 3. The agenda of TR committee in the EAGOT 2nd Annual Meeting

Session	Speaker
Session I. Developing protocol (Chair: Katsutoshi Oda)	
TGOG-4002: A retrospective, open-label, biomarker study for early-stage ovarian clear cell carcinoma (OCCC) patients at risk of recurrence	Ruby Yun-Ju Huang (TGOG)
JGOG-2052: Phase II study of niraparib in recurrent of persistent rare fraction of gynecologic malignancies with homologous recombination deficiency	Hiroshi Asano (JGOG)
Mechanisms of resistance to PARP inhibitor: current clinical evidence and translational research plan of KGOG3067/SOCCER-P (a randomized phase II study of secondary cytoreductive surgery in patients with relapsed ovarian cancer who had progressed on PARP inhibitor maintenance)	Hyun-Woong Cho (KGOG)
Session II. New study concepts (Chair: Jeong-Won Lee)	
Research perspectives in genomic evolution under neoadjuvant chemotherapy in HGSOC cohort	Jin-Ku Lee (KGOG)
JGOG-3032: Whole genome and transcriptome analysis registry study in advanced primary and recurrent ovarian cancer (from ovarian cancer committee study)	Tatsuyuki Chiyoda (JGOG)
Comprehensive genomic profiling of Taiwanese OCCC by using TSO500+HRD for clinical stratification	Ruby Yun-Ju Huang (TGOG)

EAGOT, East Asian Gynecologic Oncology Trial Group; HGSOC, high grade serous ovarian cancer; HRD, homologous recombination deficiency; JGOG, Japanese Gynecologic Oncology Group; PARP, poly (ADP-ribose) polymerase; KGOG, Korean Gynecologic Oncology Group; TGOG, Taiwanese Gynecologic Oncology Group; TR, translational research.

Table 4. The agenda of uterine corpus cancer committee in the EAGOT 2nd Annual Meeting

Agenda	Speaker
Welcome to EAGOT Korea	Min Kyu Kim (KGOG)
JGOG2054s: Isolated (Oligomet) recur EC-local Tx vs systemic (other) Tx	Mayu Yunokawa (KGOG) Discussant: Gwan Hee Han (KGOG)
REMPA TRIAL (JGOG 2051/KGOG 2031): fertility/high dose hormone	Kensuke sakai (Virtual: JGOG) Yung-Taek Ouh (KGOG)
JGOG survey report based on KGOG 2028/KROG 2104	Jiro Suzuki (JGOG) Discussant: Min Kyu Kim (KGOG) Dawn Chung (Virtual: KGOG)
Education session: liquid biopsy basics and application in clinical trial	Woochang Lee (Asan Medical Center) Discussant: Ha Kyun Chang (KGOG)
Probable first EAGOT 2001 trial- KGOG 2029 suggestion	Jeong-Yeol Park (KGOG)
EAGOT corpus discussion: practice change after FIGO 2023 (KGOG, JGOG, TGOG, CGCS)	

CGCS, Chinese Gynecologic Cancer Society; EAGOT, East Asian Gynecologic Oncology Trial Group; FIGO, International Federation of Gynecology and Obstetrics; JGOG, Japanese Gynecologic Oncology Group; KGOG, Korean Gynecologic Oncology Group; TGOG, Taiwanese Gynecologic Oncology Group.

Table 5. The agenda of ovarian cancer committee in the EAGOT 2nd Annual Meeting

Agenda	Speaker
Research status updates from each country's ovarian cancer committee	
An attempt to establish real-world databases of PARP inhibitors for advanced or recurrent epithelial ovarian cancer	
KGOG 3058: Effectiveness and safety of PARP-inhibitor maintenance therapy in recurrent ovarian cancer patients in real world; retrospective cohort study (ESPOIR)	Hyun Jin Choi (KGOG)
KGOG 3059: A cohort study to assess the safety and efficacy of PARP inhibitor maintenance after first-line therapy of Korean women with advanced ovarian/fallopian/peritoneal cancer	Eun-Ju Lee (KGOG)
New clinical trials	
KGOG 3033: Surgery alone and surveillance in FIGO stage I malignant ovarian germ cell tumor	Jeong-Yeol Park (KGOG)
KGOG 3050: Laparoscopic vs laparotomic surgery in OV CA	Jeong-Yeol Park (KGOG)
KGOG 4010: Assessment of quality of life after low anterior resection or visceral peritoneal stripping during cytoreductive surgery for advanced ovarian cancer requiring tumor resection on the rectosigmoid colon: a prospective cohort study (LAPSODY study)	Soo Jin Park (KGOG)
Proposals for international cooperation from each country	
KGOG 3020: KGOG & JGOG: Randomized phase III Trial of the need for adjuvant chemotherapy in stage I epithelial ovarian cancer after comprehensive staging surgery (ECO trial)	Jeong-Won Lee (KGOG)
JGOG 3024: KGOG & JGOG: Prospective cohort study of germline variant carriers with BRCA1 and BRCA2	
Projects you believe EAGOT ovarian committee should collaborate on	
Development of treatment for refractory rare ovarian cancer	JGOG
A randomized phase II study of secondary cytoreductive surgery in patients with relapsed ovarian cancer who have progressed on PARP inhibitor maintenance (KGOG3067/SOCCER-P study)	Hyun-Woong Cho (KGOG)

EAGOT, East Asian Gynecologic Oncology Trial Group; FIGO, International Federation of Gynecology and Obstetrics; JGOG, Japanese Gynecologic Oncology Group; PARP, poly (ADP-ribose) polymerase; KGOG, Korean Gynecologic Oncology Group; OV CA, ovarian cancer.

2. The cervical cancer committee

As shown in **Table 2**, 4 studies were presented by the cervical cancer committee members. Professor Keun Ho Lee introduced 2nd EAGOT cervical cancer committee and summarized the discussions from the 1st Annual Meeting of EAGOT. Following the presentations on 4 ongoing or upcoming clinical trials, Professor Youn Jin choi delivered a lecture on the topic of "Overcoming Radiation Resistance: Combination of Radiation and Immunotherapy." The committee members discussed clinical trials related to cervical cancer, with a particular focus on studies examining the safety of minimally invasive surgery for radical hysterectomy.

3. The translational research (TR) committee

The agenda of the TR committee consisted of 2 sessions: developing protocol and new study concepts (**Table 3**).

Three developing protocols were presented, consisting of one retrospective study and 2 phase II trials. Subsequently, Professor Jin-Ku Lee delivered a presentation of "Research perspectives in Genomic evolution under neoadjuvant chemotherapy in HGSOc cohort,"

followed by the proposal of 2 new study concepts. After the introduction of 2 new clinical studies, the committee members discussed how to gather patient data and sharing genomic data among 4 groups.

4. Industrial symposium 2 (AstraZeneca)

Industrial symposium 2 on the second day was chaired by Professor Chyong-Huey Lai (the president of TGOG) and was conducted under the title “Vision for Optimal Treatment in Ovarian Cancer.” Professor Kosuke Yoshihara (Vice-chair of TR committee, JGOG) gave a lecture entitled “Future directions of ovarian cancer treatment after the era of PARP inhibitors.” He presented the updated research findings on ovarian cancer treatment from American Society of Clinical Oncology (ASCO) 2023 and highlighted the role of SLFN11 as a novel biomarker for predicting platinum sensitivity. Rosa Kim (the senior director of AstraZeneca) delivered a lecture titled “AstraZeneca’s current and future oncology development strategy.” She provided a detailed overview of the current status of ongoing and upcoming clinical trials at AstraZeneca.

5. The uterine corpus cancer committee

After the welcome address of Professor Min Kyu Kim, 3 clinical trials from JGOG and KGOG were presented by the uterine corpus cancer committee members (**Table 4**). As the educational session, invited speaker Professor Woochang Lee (Department of Laboratory Medicine, Asan Medical Center) presented a lecture on “Liquid biopsy basics and application in clinical trial,” followed by a discussion led by Professor Ha Kyun Chang. Professor Jeong-Yeol Park proposed registering the ongoing KGOG 2029 study (Randomized comparison between sentinel lymph node mapping using indocyanine green plus a fluorescent camera versus lymph node dissection in clinical stage I–II endometrial cancer) as an EAGOT trial, allowing all 4 national groups to collaborate on it. Lastly, all members collectively discussed the changes in clinical practice following the adoption of the International Federation of Gynecology and Obstetrics (FIGO) 2023 staging system for endometrial cancer.

6. The ovarian cancer committee

The agenda of the ovarian cancer committee consisted of 3 sessions: the updated research status from each country’s ovarian cancer committee, proposals for international cooperation from each country, and projects to be collaboratively undertaken by the EAGOT ovarian cancer committee (**Table 5**). The progress of 2 KGOG studies aimed at establishing real-world databases of PARP inhibitors for advanced or recurrent epithelial ovarian cancer was presented by the committee members. Three new clinical trials protocols were proposed, all of which were prospective studies set to be conducted by KGOG. Subsequently, the progress of 2 ongoing studies jointly conducted by KGOG and JGOG was reviewed, and 2 additional studies were proposed for collaboration within EAGOT.

7. Industrial symposium 3 (MSD)

Professor Xiaohua Wu (the president of CGCS) chaired industrial symposium 3, which was held under the title “New treatment landscape in advanced endometrial cancer.” Professor Hao Wen from Fudan University gave a lecture entitled “Interpretation and application of recent immunotherapy for GYN cancer, based on the experience data in China.” He presented updated clinical trial results on various immunotherapies in gynecologic cancer patients, with a particular emphasis on the findings from studies conducted in China. Soo Yeon Ihm (the regional associate director of MSD) delivered a lecture titled “Unlocking the potential of MSD: a look into the promising future in gynecologic cancer trials.” She introduced MSD’s

clinical research programs and presented on the wide range of studies being conducted, from prevention to treatment of gynecologic cancers.

DAY 3 (SOFITEL HOTEL, SEOUL): EAGOT GENERAL MEETING AND INDUSTRIAL SYMPOSIUM 4

1. EAGOT general meeting

On the third day of the EAGOT 2nd Annual Meeting, the EAGOT general meeting was held. Representatives from each disease committee reported and summarized the key topics presented and discussed within each committee. All participants shared information on the clinical studies that were underway or planned within each disease committee. At the end of the general meeting, participants had the opportunity to ask questions and discuss the protocols and outcome analysis of the clinical studies.

2. Industrial symposium 4 (Canaria Bio)

Following the EAGOT general meeting, industrial symposium 4, titled “New treatment concept of ovarian cancer,” was chaired by Professor Aikou Okamoto (the president of JGOG). Professor Myong Cheol Lim from KGOG delivered a lecture titled “Future treatment of ovarian cancer patients with non-BRCA mutation or HRD (-).” He summarized the treatment options available for non-BRCA mutation of HRD (-) ovarian cancer patients based on the results of clinical studies conducted so far. Professor Peng-Hui Wang (the president of Taiwan Association of Gynecologic Oncologists [TAGO]) gave a lecture entitled “Front-line chemotherapy for patient with advanced ovarian cancer: FLORA-05 study with oregovomab, based on Taiwan experience.” He provided a brief overview of Oregovomab and summarized the practice patterns in front-line chemotherapy for ovarian cancer patients currently being implemented in Taiwan.

Finally, professor Yong Man Kim concluded the 2nd Annual Meeting with closing remarks. All participants engaged in a lively discussion on the strategies for conducting international clinical trials in East Asia. The meeting concluded with a commitment to the continued growth and advancement of EAGOT, looking forward to the next annual gathering.

SUPPLEMENTARY MATERIALS

Fig. S1

Council meeting of the EAGOT.

Fig. S2

Cervical cancer committee on September 2.

Fig. S3

Translational research committee on September 2.

Fig. S4

Uterine corpus cancer committee on September 2.

Fig. S5

Ovarian cancer committee on September 2.